Responses

PDF
Diltiazem overdose: a role for high-dose insulin
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Intravenous lipid emulsion for calcium channel blocker overdose: fattening up the treatment
    • Theophilus L Samuels, Anaesthetic Research Registrar
    • Other Contributors:
      • David R Uncles (Consultant Anaesthetist), Johann W Willers (Associate Specialist in Anaesthesia), and Aikaterini Papadopoulou (CT2 Trainee in Anaesthesia)

    We read with interest the case report by Abeysinghe and colleagues reporting hyperinsulinaemic euglycaemic therapy (HIET) in the treatment of a patient presenting with persistent hypotension following an overdose of the lipophilic calcium channel blocker diltiazem.[1]

    Diltiazem is extremely lipophilic with a log P value of 4.53 (a measure of lipid solubility). Thus we consider that it would have been amenable t...

    Show More
    Conflict of Interest:
    None declared.